Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Abigail B. McLeod"'
Autor:
Ace J. Hatch, Christel Rushing, Emily Bolch, Hope E. Uronis, S. David Hsu, James Leroy Wells, Abigail B. McLeod, Donna Niedzwiecki, Christy Arrowood, Kimberly L. Blackwell, John H. Strickler, P. Kelly Marcom, S. Yousuf Zafar, Michael A. Morse, Herbert Hurwitz, Ivy Altomare, Sherri Haley, Andrew B. Nixon, Fatima A. Rangwala, David Z. Chang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544ae352d7f5233576a777ba7b6f4aa4
http://link.springer.com/article/10.1186/s12885-019-6234-8
http://link.springer.com/article/10.1186/s12885-019-6234-8
Autor:
Holly M. Alley, James P. Stice, Suzanne E. Wardell, Donald P. McDonnell, Ching-Yi Chang, Abigail B. McLeod
Publikováno v:
The Prostate. 78:266-277
Background Whereas the androgen receptor (AR) signaling axis remains a therapeutic target in castration-resistant prostate cancer (CRPC), the emergence of AR mutations and splice variants as mechanisms underlying resistance to contemporary inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44b443f68bfada1297c78bbfc05f9a08
https://doi.org/10.1002/pros.23467
https://doi.org/10.1002/pros.23467